Author Archives: "Elizabeth Porco"

Elizabeth Porco

Trigeminal neuralgia, type of nerve pain, is an early multiple sclerosis symptom
Trigeminal neuralgia affects the fifth cranial nerve, trigeminal, which is responsible for the sensation in the face involved with biting [...]
Exploring new paths for the treatment of multiple sclerosis
(Edmonton) Research from the University of Alberta's Faculty of Medicine & Dentistry is trailblazing a potential new pathway for the [...]
CMSC issues position statement on Aaccess to medications to treat symptoms of multiple sclerosis
Consortium of Multiple Sclerosis Centers Issues Position Statement on Access to Medications to Treat Symptoms of MS (Hackensack, NJ, [...]
Biogen reports top-line results from phase 3 study evaluating Natalizumab in SPMS
Wednesday, October 21, 2015 7:31 am EDT CAMBRIDGE, Mass.--(BUSINESS WIRE)--The Phase 3 ASCEND study investigating natalizumab in the [...]
EMD Serono announces publication of PRISMS-15 year follow-up study using Rebif in RRMS
Rockland, Massachusetts, October 12, 2015 – EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, Germany, today [...]
Treatment effects maintained over 5 years in patients with RRMS who received Lemtrada
Thursday, October 8, 2015 1:00 am EDT CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, aSanofi company, today announced positive new [...]
Genentech’s Ocrelizumab show positive pivotal study results in both RRMS and PPMS
Genentech’s Ocrelizumab First Investigational Medicine to Show Positive Pivotal Study Results in Both Relapsing and Primary Progressive [...]
EMD Serono announces recipients of the third annual €1 million grant for multiple sclerosis innovation
EMD Serono Announces Recipients of the Third Annual €1 Million Grant for Multiple Sclerosis Innovation Four research grants awarded [...]
Results from ZINBRYTA phase 3 DECIDE study presented at ECTRIMS
Results from ZINBRYTA™ (Daclizumab High-Yield Process) Phase 3 DECIDE Study Highlighting Efficacy Compared to Interferon Beta-1a [...]
New analysis suggests Aubagio slows brain atrophy in people with Relapsing MS
New Analysis Suggests Aubagio® (teriflunomide) Slows Brain Atrophy in People with Relapsing Multiple Sclerosis Additional MRI data on [...]

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us
I have a question about
First
Last